Picture of Ascelia Pharma AB logo

ACE Ascelia Pharma AB Share Price

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m-6.84%
3m-6.64%
6m-8.36%
1yr-29.76%
Volume Change (%)
10d/3m+41.2%
Price vs... (%)
52w High-44.62%
50d MA-13.73%
200d MA-20.27%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-53.25%
Return on Equity-36.94%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Ascelia Pharma AB EPS forecast chart

Profile Summary

Ascelia Pharma AB is a Sweden-based pharmaceutical company focused on the development of novel oncology therapies. The Company identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The Company's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. It has completed phase I of clinical studies.

Directors

Last Annual
December 31st, 2021
Last Interim
June 30th, 2022
Incorporated
June 4th, 1999
Public Since
March 13th, 2019
No. of Employees
21
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
se flag iconOMX Nordic Exchange Stockholm
Shares in Issue
33,668,262
Blurred out image of a map
Address
Hyllie Boulevard 34, MALMO, 215 32
Web
https://www.ascelia.com/
Phone
+46 462863760
Contact
Mikael Widell
Auditors
Ohrlings PricewaterhouseCoopers AB

ACE Share Price Performance

Upcoming Events for ACE

Q3 2022 Ascelia Pharma AB Earnings Release

Q4 2022 Ascelia Pharma AB Earnings Release

Similar to ACE

Picture of 2cureX AB logo

2cureX AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Abliva AB logo

Abliva AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Acousort AB logo

Acousort AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Acousort AB logo

Acousort AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Active Biotech AB publ logo

Active Biotech AB publ

se flag iconOMX Nordic Exchange Stockholm

FAQ

Or unlock with your email

Or unlock with your email